NeuroCME

This activity is expired and is no longer available for CME credit.

VIDEOCME

Expert Interviews on Treatment of Multiple Sclerosis: Shifting the Paradigm in 2015

Author(s)/Faculty: Patricia K. Coyle, MD, FAAN; Bruce A. Cohen, MD
Release Date: 4/14/2015Expiration Date: 4/13/2016
Credit Type: CMENumber of Credits: 0
Content Type: MultimediaProvider:
Treatment with disease modifying therapies (DMTs) can transform the otherwise debilitating course of multiple sclerosis (MS), a progressive, inflammatory, autoimmune disease of the central nervous system. For patients with established disease, DMTs are directed toward reducing the frequency and severity of clinical attacks, slowing the progression of disability, and reducing accumulation of lesions within the brain and spinal cord. Over the last several decades, treatment options have been developed for their effect on T cells in the pathogenesis of MS. However, recent evidence has shown that B cells and humoral immunity also play a key role in MS pathogenesis, which is opening the door to new treatment options. With an expansive body of evidence and new therapies emerging, it is critical that clinicians be well-versed in emerging safety, efficacy, and tolerability data associated with existing and investigational agents. This activity will explore new findings in MS pathology and treatment, and also discuss notable differences in the disease and management of patients with progressive forms of MS.